claudin 4 (Proteintech)
Structured Review
Claudin 4, supplied by Proteintech, used in various techniques. Bioz Stars score: 99/100, based on 121 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/claudin+4/CLDN7+Fusion+Protein/pm41932000-61-5-13
Average 99 stars, based on 121 article reviews
Images
Related Articles
Incubation:Article Title: Curcumin ameliorates aging-induced blood-testis barrier disruption by regulating AMPK/mTOR mediated autophagy. Article Snippet: .. The membranes were then incubated overnight at 4 °C with specific primary antibodies: P-AMPK alphaThr172 (2535, 1:1000, Cell Signaling Technology, Danvers, Massachusetts, USA), AMPK alpha (5831s, 1:1000, Cell Signaling Technology), LC3B (ab192890, 1:2000, Abcam, Cambridge, MA, USA), Beclin1 (bs-1353R, 1:500, Bioss), P-mTOR (T56571, 1:1000, Abmart, Shanghai, China), mTOR (T55306, 1:1000,Abmart), p21 (T55543S, 1:1000, Abmart), CDKN2A (TN23895S, 1:1000, Ab-mart), Occludin (27260–1-AP, 1:1000, Proteintech, Wuhan, China), Article Title: Pharmacokinetic and Pharmacodynamic Evaluation of PZ-2891, an Anti-Alzheimer’s Disease Agonist of PANK2 Article Snippet: .. After transferring to a PVDF membrane and blocking in 5% BSA or skim milk for 2 h, blots were incubated with primary antibodies at 4 °C overnight, namely GAPDH (1:40,000, Abcam EPR16891 ), p-tau396 (1:500, CST F3S9T), Aβ (1:1000, Proteintech 25524-1-AP), GFAP (1:10,000, Proteintech 16825-1-AP), LRP1 (1:1000, Proteintech 26106-1-AP), MRP1 (1:1000, Proteintech 67228-1-Ig), PANK1 (1:1000, Proteintech 11768-1-AP), PANK2 (1:1000, Proteintech 11001-1-AP), PANK3 (1:500, SCBT sc-551231), occludin (1:2000, Proteintech 27260-1-AP), ZO-1 (1:1000, Proteintech 21773-1-AP), claudin-1 (1:1000, Proteintech 28674-1-AP) and Article Title: Curcumin ameliorates aging-induced blood-testis barrier disruption by regulating AMPK/mTOR mediated autophagy Article Snippet: .. The membranes were then incubated overnight at 4 °C with specific primary antibodies: P-AMPK alphaThr172 (2535, 1:1000, Cell Signaling Technology, Danvers, Massachusetts, USA), AMPK alpha (5831s, 1:1000, Cell Signaling Technology), LC3B (ab192890, 1:2000, Abcam, Cambridge, MA, USA), Beclin1 (bs-1353R, 1:500, Bioss), P-mTOR (T56571, 1:1000, Abmart, Shanghai, China), mTOR (T55306, 1:1000,Abmart), p21 (T55543S, 1:1000, Abmart), CDKN2A (TN23895S, 1:1000, Ab-mart), Occludin (27260–1-AP, 1:1000, Proteintech, Wuhan, China), Expressing:Article Title: Relaxin-2-secreting CAR-T cells exhibit enhanced efficacy in stromal-rich xenograft tumors. Article Snippet: The expression of CD44v6 in various cancer cell lines was assessed using a mouse anti-human FITCconjugated CD44v6 antibody (clone VFF-18, eBioscience). .. The expression of Article Title: Relaxin-2-secreting CAR-T cells exhibit enhanced efficacy in stromal-rich xenograft tumors Article Snippet: The expression of CD44v6 in various cancer cell lines was assessed using a mouse anti-human FITC-conjugated CD44v6 antibody (clone VFF-18, eBioscience). .. The expression of Transferring:Article Title: Pharmacokinetic and Pharmacodynamic Evaluation of PZ-2891, an Anti-Alzheimer’s Disease Agonist of PANK2 Article Snippet: .. After transferring to a PVDF membrane and blocking in 5% BSA or skim milk for 2 h, blots were incubated with primary antibodies at 4 °C overnight, namely GAPDH (1:40,000, Abcam EPR16891 ), p-tau396 (1:500, CST F3S9T), Aβ (1:1000, Proteintech 25524-1-AP), GFAP (1:10,000, Proteintech 16825-1-AP), LRP1 (1:1000, Proteintech 26106-1-AP), MRP1 (1:1000, Proteintech 67228-1-Ig), PANK1 (1:1000, Proteintech 11768-1-AP), PANK2 (1:1000, Proteintech 11001-1-AP), PANK3 (1:500, SCBT sc-551231), occludin (1:2000, Proteintech 27260-1-AP), ZO-1 (1:1000, Proteintech 21773-1-AP), claudin-1 (1:1000, Proteintech 28674-1-AP) and Membrane:Article Title: Pharmacokinetic and Pharmacodynamic Evaluation of PZ-2891, an Anti-Alzheimer’s Disease Agonist of PANK2 Article Snippet: .. After transferring to a PVDF membrane and blocking in 5% BSA or skim milk for 2 h, blots were incubated with primary antibodies at 4 °C overnight, namely GAPDH (1:40,000, Abcam EPR16891 ), p-tau396 (1:500, CST F3S9T), Aβ (1:1000, Proteintech 25524-1-AP), GFAP (1:10,000, Proteintech 16825-1-AP), LRP1 (1:1000, Proteintech 26106-1-AP), MRP1 (1:1000, Proteintech 67228-1-Ig), PANK1 (1:1000, Proteintech 11768-1-AP), PANK2 (1:1000, Proteintech 11001-1-AP), PANK3 (1:500, SCBT sc-551231), occludin (1:2000, Proteintech 27260-1-AP), ZO-1 (1:1000, Proteintech 21773-1-AP), claudin-1 (1:1000, Proteintech 28674-1-AP) and Blocking Assay:Article Title: Pharmacokinetic and Pharmacodynamic Evaluation of PZ-2891, an Anti-Alzheimer’s Disease Agonist of PANK2 Article Snippet: .. After transferring to a PVDF membrane and blocking in 5% BSA or skim milk for 2 h, blots were incubated with primary antibodies at 4 °C overnight, namely GAPDH (1:40,000, Abcam EPR16891 ), p-tau396 (1:500, CST F3S9T), Aβ (1:1000, Proteintech 25524-1-AP), GFAP (1:10,000, Proteintech 16825-1-AP), LRP1 (1:1000, Proteintech 26106-1-AP), MRP1 (1:1000, Proteintech 67228-1-Ig), PANK1 (1:1000, Proteintech 11768-1-AP), PANK2 (1:1000, Proteintech 11001-1-AP), PANK3 (1:500, SCBT sc-551231), occludin (1:2000, Proteintech 27260-1-AP), ZO-1 (1:1000, Proteintech 21773-1-AP), claudin-1 (1:1000, Proteintech 28674-1-AP) and Immunohistochemistry:Article Title: p38 MAPK-mediated upregulation of claudin-3 and claudin-4 by gemcitabine contributes to chemoresistance in ovarian cancer. Article Snippet: Chemotherapy is a primary therapeutic option in cancer treatment, but often associated with unwanted side effects and drug resistance.. Claudin-3 (CLDN3) and claudin-4 (CLDN4) are essential components of tight junctions, frequently overexpressed in ovarian cancer, serve as potential therapeutic targets.. In this study, we utilized flow cytometry, qPCR, Western blot, and animal experiments to investigate the regulation of CLDN3 and CLDN4 by chemotherapy drug, gemcitabine, in the ovarian cancer cell line A2780. Staining:Article Title: p38 MAPK-mediated upregulation of claudin-3 and claudin-4 by gemcitabine contributes to chemoresistance in ovarian cancer. Article Snippet: Chemotherapy is a primary therapeutic option in cancer treatment, but often associated with unwanted side effects and drug resistance.. Claudin-3 (CLDN3) and claudin-4 (CLDN4) are essential components of tight junctions, frequently overexpressed in ovarian cancer, serve as potential therapeutic targets.. In this study, we utilized flow cytometry, qPCR, Western blot, and animal experiments to investigate the regulation of CLDN3 and CLDN4 by chemotherapy drug, gemcitabine, in the ovarian cancer cell line A2780. |
